Our in vitro and in vivo experiments with peripheral nerve sheath tumor cells and animal models clearly suggest that targeting the IL13Rα2 with IL13 conjugated liposomes will increase the accumulation of the drug in the tumor and subsequently decrease the tumor burden. The gene discussed is IL13RA2; the disease is neoplasm.